AstraZeneca acquire Omthera Pharmaceuticals $323 million

AstraZeneca to acquire Omthera Pharmaceuticals for $323 million

4:58 AM, 31st May 2013
AstraZeneca to acquire Omthera Pharmaceuticals for $323 million
Pascal Soriot, Chief Executive Officer, AstraZeneca.

LONDON, UK: AstraZeneca has entered into a definitive agreement to acquire Omthera Pharmaceuticals, a specialty pharmaceutical company based in Princeton, New Jersey, focused on the development and commercialisation of new therapies for abnormal levels of lipids in the blood, referred to as dyslipidemia.

AstraZeneca will acquire Omthera for $12.70 per share, or approximately $323 million, which has an Enterprise Value of approximately $260 million after incorporating Omthera’s cash balances of approximately $63 million. This represents a premium of 88 per cent on Omthera’s closing price on 24 May 2013. In addition to the cash payment, each Omthera shareholder will receive Contingent Value Rights (CVRs) of up to approximately $4.70 per share, equating to approximately $120 million in total, if specified milestones related to Epanova are achieved, or if a milestone related to global net sales is achieved. This will bring the total potential acquisition cost to approximately $443 million.

“The number of people with elevated triglyceride levels is rising rapidly across the world, due in part to the increasing prevalence of obesity and diabetes. There is a clear need for effective and convenient alternatives to some of the existing treatments. Epanova offers real potential both as a distinctive monotherapy for the treatment of hypertriglyceridemia and in combination with Crestor for patients at high risk of adverse cardiovascular events. This is an exciting acquisition that clearly complements our existing portfolio in cardiovascular and metabolic disease, one of our core therapy areas,” said Pascal Soriot, Chief Executive Officer, AstraZeneca.

© WOC News

Worldofchemicals provides news updates on polymer chemistry, green chemistry, industrial chemistry, biochemistry, organic chemistry etc - https://www.worldofchemicals.com/media/index.html

0 Comments

Login

Your Comments (Up to 2000 characters)
Please respect our community and the integrity of its participants. WOC reserves the right to moderate and approve your comment.

Related News


Showa Denko to increase production capacity for aluminum laminated films

TOKYO, JAPAN: Showa Denko Packaging Co Ltd, a subsidiary of Showa Denko KK (SDK), has decided to increase its production capacity for aluminum laminat ...

Read more
Praxair acquires Dominion Technology Gases

DANBURY, US: Praxair Offshore Services Limited, a subsidiary of Praxair Inc, has acquired Aberdeen, Scotland-based Dominion Technology Gases Investmen ...

Read more
ExxonMobil expands ethylene cracker in Singapore

SINGAPORE: ExxonMobil’s Singapore Chemical Plant is now producing ethylene from the facility’s second world-scale steam cracker. The expan ...

Read more
BASF, Sinopec expand ethylene oxide production in Nanjing, China

LUDWIGSHAFEN, GERMANY/NANJING, CHINA: BASF and Sinopec are considering the extension of their Nanjing joint venture BASF-YPC Company Limited with the ...

Read more
Amgen, Astellas to provide new medicines in Japan

TOKYO, JAPAN: Amgen Inc, the world’s largest biotechnology company, entered into a long-term collaboration with Astellas Pharma Inc and will for ...

Read more
Bayer gets US FTC clearance for acquisition of Conceptus

LEVERKUSEN, GERMANY: Antitrust clearance from the US Federal Trade Commission (FTC) was obtained with respect to Bayer’s acquisition of Conceptu ...

Read more
www.worldofchemicals.com uses cookies to ensure that we give you the best experience on our website. By using this site, you agree to our Privacy Policy and our Terms of Use. X